Journal
EXPERT OPINION ON DRUG SAFETY
Volume 12, Issue 5, Pages 673-685Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/14740338.2013.804059
Keywords
aprepitant; casopitant; clinical trial; CP-122,721; ezlopitant; fosaprepitant; NK-1 receptor antagonists; safety; side effects; tolerability; vofopitant
Categories
Ask authors/readers for more resources
Introduction: The substance P (SP)/neurokinin (NK)-1 receptor system is involved in many pathological processes. NK-1 receptor antagonists have many promising therapeutic indications. However, the only NK-1 receptor antagonist used in clinical practice is the drug aprepitant and its intravenously administered prodrug, fosaprepitant. In general, NK-1 receptor antagonists are safe and well tolerated. Areas covered: A search was carried out in Medline using the following terms: adverse events, aprepitant, casopitant, clinical trials, CP-122,721, ezlopitant, fosaprepitant, NK-1 receptor antagonists, randomized, safety, side effects, tolerability and vofopitant. Expert opinion: Most clinical trials have focused on the antiemetic action of aprepitant in cancer patients treated with chemotherapy. However, the efficacy and safety of aprepitant have not been fully tested in other diseases in which the SP/NK-1 receptor system is involved (e. g., cancer, HIV, alcoholism); thus, clinical trials are required. The use of NK-1 receptor antagonists in oncology therapy is quite promising, but to date pharmacological therapy has not exploited the many possible therapies offered by such antagonists.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available